leisure time -WSS

leisure time

author：hotspot 2025-09-27 22:18:17 - browse：89566

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： PrEP can help anyone prevent HIV. Why do so few people take it?

hotspot

WSS

People with substance use disorder deserve online privacy

Statins reduce cardiovascular risk in people living with HIV

The struggle to figure out which patients 'deserve' Wegovy

What happened to the House vote on health price transparency?

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Patients, doctors press FTC to beef up hospital merger scrutiny

knowledge

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Virginia high school admissions case could be legal follow

4 missing after record

Novavax promises a turnaround & Lilly roils the obesity market

FAMU bans football players from facility after release of rap video shot in team's locker room

Malaria cases in Florida and Texas: Here’s what you need to know

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Heart attack and stroke risk calculators need revising

House panel takes first step toward fixing drug shortages

hotspot

The response to Covid

What Henrietta Lacks's story taught me about my role as a doctor

FDA panel to weigh safety of artificial wombs for preterm births

Eli Lilly CEO gives to Mike Pence presidential super PAC

Novartis develops a rapidly manufactured CAR

How the messy conversation about Dolly changed bioethics

explore

focus

hotspot

focus